Annual Operating Profit
-$314.49 M
+$21.04 M+6.27%
31 December 2023
Summary:
Allogene Therapeutics annual operaing income is currently -$314.49 million, with the most recent change of +$21.04 million (+6.27%) on 31 December 2023. During the last 3 years, it has fallen by -$56.25 million (-21.78%). ALLO annual operating profit is now -74.53% below its all-time high of -$180.19 million, reached on 31 December 2021.ALLO Operating Profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Operating Profit
-$61.05 M
+$5.40 M+8.12%
30 September 2024
Summary:
Allogene Therapeutics quarterly operating income is currently -$61.05 million, with the most recent change of +$5.40 million (+8.12%) on 30 September 2024. Over the past year, it has increased by +$1.95 million (+3.10%). ALLO quarterly operating profit is now -3676.22% below its all-time high of $1.71 million, reached on 31 December 2021.ALLO Quarterly Operating Profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM Operating Profit
-$268.86 M
+$1.95 M+0.72%
30 September 2024
Summary:
Allogene Therapeutics TTM operating income is currently -$268.86 million, with the most recent change of +$1.95 million (+0.72%) on 30 September 2024. Over the past year, it has increased by +$70.23 million (+20.71%). ALLO TTM operating profit is now -10252.56% below its all-time high of -$2.60 million, reached on 31 March 2018.ALLO TTM Operating Profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ALLO Operating Profit Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +6.3% | +3.1% | +20.7% |
| 3 y3 years | -21.8% | +21.4% | -7.0% |
| 5 y5 years | -63.1% | -11.0% | -57.7% |
ALLO Operating Profit High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -74.5% | +6.3% | -3676.2% | +38.4% | -49.2% | +25.0% |
| 5 y | 5 years | -74.5% | +6.3% | -3676.2% | +38.4% | -57.7% | +25.0% |
| alltime | all time | -74.5% | +6.3% | -3676.2% | +54.8% | <-9999.0% | +25.0% |
Allogene Therapeutics Operating Profit History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$61.05 M(-8.1%) | -$268.86 M(-0.7%) |
| June 2024 | - | -$66.44 M(-4.4%) | -$270.81 M(-4.9%) |
| Mar 2024 | - | -$69.50 M(-3.3%) | -$284.90 M(-9.4%) |
| Dec 2023 | -$314.49 M(-6.3%) | -$71.86 M(+14.1%) | -$314.49 M(-7.3%) |
| Sept 2023 | - | -$63.00 M(-21.8%) | -$339.09 M(-5.4%) |
| June 2023 | - | -$80.54 M(-18.7%) | -$358.58 M(+1.1%) |
| Mar 2023 | - | -$99.09 M(+2.7%) | -$354.64 M(+5.7%) |
| Dec 2022 | -$335.54 M(+86.2%) | -$96.46 M(+16.9%) | -$335.54 M(+41.4%) |
| Sept 2022 | - | -$82.49 M(+7.7%) | -$237.37 M(+2.1%) |
| June 2022 | - | -$76.59 M(-4.2%) | -$232.55 M(+2.5%) |
| Mar 2022 | - | -$79.99 M(-4786.1%) | -$226.98 M(+26.0%) |
| Dec 2021 | -$180.19 M | $1.71 M(-102.2%) | -$180.19 M(-28.3%) |
| Sept 2021 | - | -$77.67 M(+9.3%) | -$251.26 M(+4.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2021 | - | -$71.03 M(+113.9%) | -$241.63 M(+3.4%) |
| Mar 2021 | - | -$33.20 M(-52.1%) | -$233.76 M(-9.5%) |
| Dec 2020 | -$258.24 M(+27.8%) | -$69.36 M(+1.9%) | -$258.24 M(+1.9%) |
| Sept 2020 | - | -$68.04 M(+7.7%) | -$253.46 M(+5.4%) |
| June 2020 | - | -$63.16 M(+9.5%) | -$240.43 M(+7.7%) |
| Mar 2020 | - | -$57.68 M(-10.7%) | -$223.23 M(+10.5%) |
| Dec 2019 | -$202.01 M(+4.8%) | -$64.58 M(+17.4%) | -$202.01 M(+18.5%) |
| Sept 2019 | - | -$55.01 M(+19.7%) | -$170.48 M(+23.8%) |
| June 2019 | - | -$45.96 M(+26.1%) | -$137.66 M(-39.3%) |
| Mar 2019 | - | -$36.46 M(+10.3%) | -$226.71 M(+17.6%) |
| Dec 2018 | -$192.84 M | -$33.05 M(+48.9%) | -$192.84 M(+20.7%) |
| Sept 2018 | - | -$22.19 M(-83.6%) | -$159.80 M(+16.1%) |
| June 2018 | - | -$135.01 M(+5098.8%) | -$137.61 M(+5198.8%) |
| Mar 2018 | - | -$2.60 M | -$2.60 M |
FAQ
- What is Allogene Therapeutics annual operaing income?
- What is the all time high annual operating profit for Allogene Therapeutics?
- What is Allogene Therapeutics annual operating profit year-on-year change?
- What is Allogene Therapeutics quarterly operating income?
- What is the all time high quarterly operating profit for Allogene Therapeutics?
- What is Allogene Therapeutics quarterly operating profit year-on-year change?
- What is Allogene Therapeutics TTM operating income?
- What is the all time high TTM operating profit for Allogene Therapeutics?
- What is Allogene Therapeutics TTM operating profit year-on-year change?
What is Allogene Therapeutics annual operaing income?
The current annual operating profit of ALLO is -$314.49 M
What is the all time high annual operating profit for Allogene Therapeutics?
Allogene Therapeutics all-time high annual operaing income is -$180.19 M
What is Allogene Therapeutics annual operating profit year-on-year change?
Over the past year, ALLO annual operaing income has changed by +$21.04 M (+6.27%)
What is Allogene Therapeutics quarterly operating income?
The current quarterly operating profit of ALLO is -$61.05 M
What is the all time high quarterly operating profit for Allogene Therapeutics?
Allogene Therapeutics all-time high quarterly operating income is $1.71 M
What is Allogene Therapeutics quarterly operating profit year-on-year change?
Over the past year, ALLO quarterly operating income has changed by +$1.95 M (+3.10%)
What is Allogene Therapeutics TTM operating income?
The current TTM operating profit of ALLO is -$268.86 M
What is the all time high TTM operating profit for Allogene Therapeutics?
Allogene Therapeutics all-time high TTM operating income is -$2.60 M
What is Allogene Therapeutics TTM operating profit year-on-year change?
Over the past year, ALLO TTM operating income has changed by +$70.23 M (+20.71%)